

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

**Single Technology Appraisal (STA)**

**Mifamurtide for Osteosarcoma**

**Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)**

<b>Version of matrix of consultees and commentators reviewed:</b> Provisional matrix of consultees and commentators sent for consultation				
<b><i>Summary of comments, action taken, and justification of action:</i></b>				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of mifamurtide for osteosarcoma

Issue date: August 2008

1.	<p><i>Should consider addition of EURODIS (European organization for rare diseases) or comparable UK patient advocate group. Should consider deleting groups with focus on Ewing's sarcoma or Paget's disease as they are not relevant to this technology appraisal.</i></p>	<p><i>IDM Pharma, Inc</i></p>	<p><i>Not added</i></p>	<p><i>This organisation does not fit the inclusion criteria in regards to national organisations therefore EURODIS (European organization for rare diseases) have not been added. The groups suggested for deletion meet the inclusion criteria therefore have remained on the matrix.</i></p>
----	--	-------------------------------	-------------------------	--

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of mifamurtide for osteosarcoma

Issue date: August 2008

2.	<p><i>We would like BCRT to be considered as a "Consultee" organisation rather than Commentator. BCRT is a joint venture between parents/patients and professionals and whilst research is one element of work, so is patient/family support. We have a national and even international focus. Our work can be seen on website <a href="http://www.bonecancerresearch.org.uk">www.bonecancerresearch.org.uk</a></i></p>	<p><i>Bone Cancer Research Trust</i></p>	<p><i>Added</i></p>	<p><i>The organisation fits the inclusion criteria to be added to the Patient organisations, therefore Bone Cancer Research Trust have been added to the Patient groups.</i></p>
----	---	--	---------------------	--

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of mifamurtide for osteosarcoma

Issue date: August 2008

3.	<p><i>PPIP would like you to consider the following two young person cancer charities, as added to the ALL (17<sup>th</sup> wave) and melanoma (CB2) matrices recently signed off:</i></p> <p>a) National Children's Bureau</p> <p>b) NCH – the Children's Charity</p>		<p><i>Added</i></p>	<p><i>The National Children's Bureau fits the inclusion criteria therefore The National Children's Bureau have been added to the matrix.</i></p> <p><i>NCH – the Children's Charity fits the inclusion criteria therefore The National Children's Bureau have been added to the matrix.</i></p>
----	--	--	---------------------	---

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of mifamurtide for osteosarcoma

Issue date: August 2008